CMS approves Wash. state Medicaid payment model for Hepatitis C drugs

The Centers for Medicare & Medicaid Services yesterday approved a Medicaid state plan amendment allowing Washington state to negotiate supplemental rebate agreements with drug makers based on value. CMS has approved similar state plan amendments for Oklahoma, Michigan and Colorado, but this is the first to focus on Hepatitis C drugs. Specifically, it allows the state to negotiate under a subscription model to pay a fixed annual amount to purchase an unrestricted supply of Hepatitis C drugs.
Related News Articles
Headline
The AHA April 30 released a report highlighting how hospitals and health systems continue to experience significant financial headwinds that can challenge…
News
The AHA April 29 urged majority and minority leaders in both the Senate and House to not make disruptive policy changes to Medicaid and other coverage options…
Headline
The Supreme Court April 29 ruled 7-2 in favor of the Department of Health and Human Services in a case that challenged how HHS applied Congress’ formula for…
Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation…
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from…
Headline
A Minnesota state court April 15 dismissed a lawsuit filed by PhRMA challenging the state’s law protecting 340B pricing for contract pharmacy arrangements. The…